Clinical Trial Update: An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 open-label study of E7820 in unresectable solid tumors to determine maximum tolerated dose and assess pharmacodynamics/pharmacokinetics with twice-daily…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• E7820

Snippet

Sponsor: Eisai Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2020-01-18